ReviewPLoS pathogens2020
Candida auris: Epidemiology, biology, antifungal resistance, and virulence.
Review in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 343 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
343 citing papers in PubMed, 2 syntheses or guidelines pooled it, 572 citations in OpenAlex.
- Candida auris-a systematic review to inform the world health organization fungal priority pathogens list.Medical mycology · 2024Pooled it
- Candida spondylodiscitis: a systematic review and meta-analysis of seventy two studies.International orthopaedics · 2024Pooled it
- Review
- Using Phenotypic, Biochemical, and Molecular Methods to IdentifyEpidemiologia (Basel, Switzerland) · 2026Article
- Multicenter performance evaluation of the SimplexaJournal of clinical microbiology · 2026Article
- From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression.MicrobiologyOpen · 2026Review
- The urgent and challenging superbug fungus Candidozyma auris (formerly Candida auris): a comprehensive review.Antonie van Leeuwenhoek · 2026Review
- Contrasting Biofilm-Modulating Effects of Polymeric Quaternary Ammonium Compounds on the Pathogenic YeastsACS omega · 2026Article
- Field Evaluation of the ClaID PCR System Reveals Predominance of Clade I-Associated Molecular Profiles Among ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Clinical Outcomes ofJournal of fungi (Basel, Switzerland) · 2026Article
- Molecular Epidemiology ofOpen forum infectious diseases · 2026Article
- Article
- Comparative Analysis of Virulence Traits and Fluconazole-Response Mechanisms in Clinical Isolates ofMicroorganisms · 2026Article
- Passive sampling of hospital wastewater as a promising warning signal for Candidozyma auris in a low-prevalence setting: a proof-of-concept study.Antimicrobial resistance and infection control · 2026Article
- The Wor2 phenotypic switching regulator controls biofilm formation in Candida auris.NPJ biofilms and microbiomes · 2026Article
- Emerging fungal threats from the environment-a lesson from Candida auris and a warning about a second candidate, Rhodosporidiobolus fluvialis.PLoS pathogens · 2026Article
- Diabetes and Immunosuppression Drive Distinct Patterns ofbioRxiv : the preprint server for biology · 2026Article
- Effect of the BD132 Dendron AgainstPharmaceutics · 2026Article
- Updated Genomic Epidemiologic Description of Candida (Candidozyma) auris, United States.Emerging infectious diseases · 2026Article
- Emergence and Genomic Profiling of Multidrug-Resistant Candida auris Isolated from Intensive Care Unit Patients in a Malaysian Teaching Hospital.Mycopathologia · 2026Article
283 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
First described in 2009 in Japan, the emerging multidrug-resistant fungal pathogen Candida auris is becoming a worldwide public health threat that has been attracting considerable attention due to its rapid and widespread emergence over the past decade. The reasons behind the recent emergence of this fungus remain a mystery to date. Genetic analyses indicate that this fungal pathogen emerged simultaneously in several different continents, where 5 genetically distinct clades of C. auris were isolated from distinct geographical locations. Although C. auris belongs to the CTG clade (its constituent species translate the CTG codon as serine instead of leucine, as in the standard code), C. auris is a haploid fungal species that is more closely related to the haploid and often multidrug-resistant species Candida haemulonii and Candida lusitaniae and is distantly related to the diploid and clinically common fungal pathogens Candida albicans and Candida tropicalis. Infections and outbreaks caused by C. auris in hospitals settings have been rising over the past several years. Difficulty in its identification, multidrug resistance properties, evolution of virulence factors, associated high mortality rates in patients, and long-term survival on surfaces in the environment make C. auris particularly problematic in clinical settings. Here, we review progress made over the past decade on the biological and clinical aspects of C. auris. Future efforts should be directed toward understanding the mechanistic details of its biology, epidemiology, antifungal resistance, and pathogenesis with a goal of developing novel tools and methods for the prevention, diagnosis, and treatment of C. auris infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.